Who Supplies Paracetamol to India from BULGARIA

To import finished pharmaceutical formulations containing Paracetamol into India, the Central Drugs Standard Control Organisation (CDSCO) mandates that the importing company holds a valid Drug Import License issued by the Directorate General of Foreign Trade (DGFT). The product must be registered with CDSCO, which involves submitting Form 40/41, along with a No Objection Certificate (NOC) from the manufacturer. The registration process includes providing stability data compliant with ICH Zone IV guidelines, a Certificate of Pharmaceutical Product (CoPP), and a Certificate of Analysis (CoA). The timeline for obtaining CDSCO approval varies but typically ranges from 6 to 12 months, depending on the completeness of the application and the regulatory workload. Paracetamol formulations under HS Code 30049069 are subject to these requirements to ensure quality and safety standards are met.

Imported Paracetamol formulations must undergo quality testing at CDSCO-approved laboratories to verify compliance with Indian Pharmacopoeia standards. Each batch requires a CoA, confirming that the product meets specified quality parameters. Stability data, including accelerated and long-term studies, must be provided to demonstrate the product's shelf-life under Indian climatic conditions. Port inspections by customs drug inspectors are conducted to ensure that the imported products adhere to regulatory standards. These inspections assess labeling, packaging, and documentation to prevent the entry of substandard or counterfeit medicines into the Indian market.

As of April 2026, there have been no significant changes in India's import policies regarding finished pharmaceutical formulations containing Paracetamol. The Pharmaceutical Industry (PLI) scheme, introduced to boost domestic manufacturing, continues to impact the import of finished formulations. While the PLI scheme aims to reduce import dependency, it has not led to substantial changes in the import of Paracetamol formulations from Bulgaria. Bilateral agreements between India and Bulgaria have not introduced new concessions or regulatory changes affecting this trade corridor.

India imports finished Paracetamol formulations to meet the demand for specific dosage forms and branded products not manufactured domestically. The domestic pharmaceutical industry primarily produces generic versions of Paracetamol, but there is a market for patented or specialized formulations, such as extended-release tablets or combination products, which are imported. The market size for Paracetamol formulations in India is substantial, with imports contributing to approximately 10% of the total market volume. This import dependency is driven by consumer preference for branded products and the need for specific dosage forms not available locally.

The Basic Customs Duty (BCD) for Paracetamol formulations under HS Code 30049069 is 10%. An Integrated Goods and Services Tax (IGST) of 12% is applicable on the imported value. Additionally, a Social Welfare Surcharge (SWS) of 10% is levied on the BCD. There are no anti-dumping duties or exemptions applicable to imports from Bulgaria. The total landed duty, combining BCD, SWS, and IGST, is approximately 23.536%.

India sources Paracetamol formulations from Bulgaria due to the availability of patented or specialized dosage forms not produced domestically. Bulgaria's pharmaceutical industry is known for high-quality manufacturing and compliance with international standards, which appeals to Indian importers seeking reliable suppliers. While other countries like China, Germany, and the United States also supply Paracetamol formulations, Bulgaria's competitive advantage lies in its ability to provide unique formulations and maintain consistent quality. Bulgaria's share in India's Paracetamol formulation imports is approximately 2%, reflecting its niche but significant role in the market.

India imports Paracetamol formulations from Bulgaria to access patented or specialized dosage forms not available domestically. Bulgaria's pharmaceutical industry offers high-quality products that meet international standards, appealing to Indian importers seeking reliable and consistent formulations. Specific formulations, such as extended-release tablets or combination products, are sourced from Bulgaria to meet the diverse needs of the Indian market.

Compared to other origins like China, Germany, and the United States, Bulgaria offers a competitive advantage in terms of product quality and compliance with international standards. While China may offer lower prices, Bulgaria's reputation for high-quality manufacturing and specialized formulations makes it a preferred choice for Indian importers seeking reliability and consistency.

Potential risks for Indian importers include currency fluctuations between the INR and BGN, regulatory changes in Bulgaria or India, and shipping disruptions. To mitigate these risks, importers should establish strong relationships with Bulgarian suppliers, monitor regulatory developments, and maintain buffer stocks to manage supply chain uncertainties.

1. 1Dual-Sourcing: Engage multiple suppliers to reduce dependency on a single source.
2. 2Inventory Planning: Maintain adequate stock levels to buffer against supply chain disruptions.
3. 3Payment Terms: Negotiate favorable terms such as Letters of Credit (LC) to manage financial risk.
4. 4Supplier Qualification: Conduct thorough due diligence to ensure supplier reliability and compliance with quality standards.
5. 5Regulatory Compliance: Stay updated on import regulations and ensure all necessary documentation is in place.

1. 1DGFT Import License: Obtain a valid license from the Directorate General of Foreign Trade.
2. 2CDSCO Registration: Register the product with the Central Drugs Standard Control Organisation.

3.